UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
TORONTO, April 02, 2024 Arch Biopartners Inc., , announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and.
TORONTO, Feb. 27, 2024 Arch Biopartners Inc., , announced today that it had a pre-investigational new drug application meeting with the U.S. Food and Drug Administration Division of.
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it.